| |
|
Parkinson's Disease
Parkinson's disease is a chronic, progressive movement disorder marked by tremors, rigidity, slow movements and postural instability. An estimated four million people suffer from Parkinson's disease worldwide, including more than one million individuals in the United States. The global market for drugs used to treat Parkinson's disease exceeds $3.5 billion annually.1 The economic burden to patients and healthcare payers is expected to increase as the prevalence of Parkinson's disease increases, fueled by the aging population. Estimates suggest that the number of treated Parkinson’s patients will grow from the current 650,000 to over 900,000 by 2020.
Treatment of Parkinson's Disease
Current treatment strategies for Parkinson's disease focus on alleviating symptoms, which require a complex cocktail of drugs that are modified as the disease progresses and symptoms become harder to manage. Levodopa is currently the gold standard for symptomatic treatment of Parkinson’s disease with over 70%1 of patients receiving the drug. One of the most common, debilitating side effects associated with treatment of Parkinson’s disease is levodopa-induced dyskinesia (LID), which represents one of the most significant challenges in the management of Parkinson’s disease. Amantadine is often prescribed to treat Parkinson’s disease, including LID, however it is underutilized due to inadequate dose-efficacy data for LID, poor tolerability and the multiple daily dosing required by current formulations.
Adamas' Parkinson's Disease Program
Adamas is developing an extended release form of amantadine (ADS-5102) to be the first product indicated for levodopa-induced dyskinesia in Parkinson’s patients. ADS-5102 is designed with a unique PK profile to overcome the poor tolerability associated with the current, immediate release forms of amantadine, enabling a higher plasma level and more robust clinical benefit. In addition, ADS-5102 provides the convenience of once daily dosing and can be sprinkled on food.
1 Source: IMS
Back to top »
|
|
